Scholarlink

Purpose <p>Combined hepatocellular–cholangiocarcinoma (cHCC-CCA) is a rare, biologically heterogeneous primary liver cancer with conflicting reported outcomes. The prognostic impact of viral hepatitis in cHCC-CCA remains unclear. Given its established influence in hepatocellular carcinoma, we evaluated whether viral etiology is associated with distinct clinical and genomic features in cHCC-CCA.</p> Methods <p>A structured PubMed and Embase search identified case reports and series describing viral status, treatment, and overall survival (OS) in cHCC-CCA. Studies lacking OS attribution or viral status were excluded. Due to heterogeneous follow-up and absence of standardized censoring, survival was analyzed descriptively, with viral versus non-viral OS compared using Mann–Whitney U testing. A complementary genomic cohort from cBioPortal was analyzed to compare mutation frequencies between viral and non-viral cases.</p> Results <p>Median OS was 49.5 months for viral versus 20.0 months for non-viral disease (mean 47.7 ± 18.5 vs 29.6 ± 16.2 months; <i>p</i> = 0.023). A crude hazard approximation suggested lower mortality risk in viral cases (HR ≈ 0.40), though formal time-to-event analysis was not feasible. In the genomic cohort, viral cases similarly demonstrated longer mean OS (23.1 vs 13.0 months; p &lt; 0.05). Non-viral tumors showed enrichment of mutations including <i>IDH, SLC16A1, CLDN18, HMCN1, ADAMTS8, BNC1, YES1,</i> and <i>TGFBR1</i>.</p> Conclusion <p>Viral cHCC-CCA was associated with longer observed survival across clinical and genomic datasets. Non-viral tumors demonstrated enrichment of mutations associated with metabolic reprogramming, proliferative signaling, pathway escape, and metastatic biology, potentially contributing to poorer outcomes. These hypothesis-generating findings require validation in prospective cohorts with standardized genomic annotation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Viral vs. Non-Viral Combined Hepatocellular–Cholangiocarcinoma: Distinct Genomic Landscapes and Survival Outcomes

  • 期刊论文

  • 发表日期：

    2026年5月18日

查看全文
  • Neha Puttagunta,
  • Matthew Friedman,
  • Binny Khandakar,
  • Timothy J. Brown,
  • Udhayvir Singh Grewal,
  • Nicholas Hornstein

摘要

Purpose

Combined hepatocellular–cholangiocarcinoma (cHCC-CCA) is a rare, biologically heterogeneous primary liver cancer with conflicting reported outcomes. The prognostic impact of viral hepatitis in cHCC-CCA remains unclear. Given its established influence in hepatocellular carcinoma, we evaluated whether viral etiology is associated with distinct clinical and genomic features in cHCC-CCA.

Methods

A structured PubMed and Embase search identified case reports and series describing viral status, treatment, and overall survival (OS) in cHCC-CCA. Studies lacking OS attribution or viral status were excluded. Due to heterogeneous follow-up and absence of standardized censoring, survival was analyzed descriptively, with viral versus non-viral OS compared using Mann–Whitney U testing. A complementary genomic cohort from cBioPortal was analyzed to compare mutation frequencies between viral and non-viral cases.

Results

Median OS was 49.5 months for viral versus 20.0 months for non-viral disease (mean 47.7 ± 18.5 vs 29.6 ± 16.2 months; p = 0.023). A crude hazard approximation suggested lower mortality risk in viral cases (HR ≈ 0.40), though formal time-to-event analysis was not feasible. In the genomic cohort, viral cases similarly demonstrated longer mean OS (23.1 vs 13.0 months; p < 0.05). Non-viral tumors showed enrichment of mutations including IDH, SLC16A1, CLDN18, HMCN1, ADAMTS8, BNC1, YES1, and TGFBR1.

Conclusion

Viral cHCC-CCA was associated with longer observed survival across clinical and genomic datasets. Non-viral tumors demonstrated enrichment of mutations associated with metabolic reprogramming, proliferative signaling, pathway escape, and metastatic biology, potentially contributing to poorer outcomes. These hypothesis-generating findings require validation in prospective cohorts with standardized genomic annotation.